Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β<sub>2</sub> Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases-Reference-Cited by-同舟云学术

Discovery, Multiparametric Optimization, and Solid-State Driven Identification of CHF-6550, a Novel Soft Dual Pharmacology Muscarinic Antagonist and β₂ Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Published:2024-06-10 Issue:12 Volume:67 Page:9816-9841
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Carzaniga Laura¹^ORCID,Linney Ian D.²,Rizzi Andrea¹^ORCID,Schmidt Wolfgang²,Knight Christopher K.²,Mileo Valentina³,Amadei Francesco³,Pastore Fiorella⁴,Miglietta Daniela⁴,Cesari Nicola⁵,Riccardi Benedetta⁵,Mazzucato Roberta¹,Ghidini Eleonora¹^ORCID,Blackaby Wesley P.²,Patacchini Riccardo⁶,Battipaglia Loredana⁷,Villetti Gino⁴,Puccini Paola⁵,Catinella Silvia³,Civelli Maurizio⁸,Rancati Fabio¹

Affiliation:

1. Medicinal Chemistry and Drug Discovery Technologies Department, Chiesi Farmaceutici S.p.A., Research Center, Largo Belloli 11/a, 43122 Parma, Italy

2. Medicinal Chemistry Department, Charles River, Chesterford Research Park, Saffron Walden, CB10 1XL, Essex United Kingdom

3. Analytics and Early Formulations Department, Chiesi Farmaceutici S.p.A., Research Center, Largo Belloli 11/a, 43122 Parma, Italy

4. Pharmacology Department, Chiesi Farmaceutici S.p.A., Research Center, Largo Belloli 11/a, 43122 Parma, Italy

5. Pharmacokinetics Biochemistry and Metabolism Department, Chiesi Farmaceutici S.p.A., Research Center, Largo Belloli 11/a, 43122 Parma, Italy

6. AIR Franchise, Chiesi Farmaceutici S.p.A., Research Center, Largo Belloli 11/a, 43122 Parma, Italy

7. Safety and Toxicology Department, Chiesi Farmaceutici S.p.A., Research Center, Largo Belloli 11/a, 43122 Parma, Italy

8. Head of Global Research & Preclinical Development, Chiesi Farmaceutici S.p.A., Research Center, Largo Belloli 11/a, 43122 Parma, Italy

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00298

Reference30 articles.

1. Goals of COPD treatment: Focus on symptoms and exacerbations

2. The economic burden of chronic obstructive pulmonary disease (COPD) in the USA, Europe, and Asia: results from a systematic review of the literature

3. New insights into the optimal management of COPD: extracts from CHEST 2021 annual meeting (October 17–20, 2021)

4. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD